Louise Frederika Kooij

Louise Frederika Kooij (CAO) sells 40,000 shares at $30.20 avg for $1.2M via scheduled 10b5-1 plan at NAMS

Louise Frederika Kooij, Chief Accounting Officer, executed 2 separate sales totaling 40,000 shares for $1,208,159.00 on 2026-06-22 under a pre-arranged 10b5-1 trading plan. Her non-derivative holdings declined from 64,353 to 24,353 shares, a reduction of 62.2%. The company is unprofitable with net income of $-48,441,000.00 in the latest quarter and annual revenue growth of -50.6%. The stock is currently trading at $32.63, above the blended sale price of $30.20 but down 22.7% from its 52-week high of $42.20. Kooij's prior sales at this ticker show mixed outcomes: 30-day returns ranged from +4.7% to +11.5%, while 90-day returns were consistently negative, ranging from -6.6% to -11.2%.

CAO Louise Kooij sells 65,000 NAMS shares at $35.69 under 10b5-1 plan; retains 24,353 non-derivative shares plus 148,149 derivative holdings

Louise Frederika Kooij, Chief Accounting Officer, sold 65,000 shares (65.0K shares) valued at $2,319,850.00 ($2.3M) on 2026-05-26 at $35.69 per share as part of a pre-arranged 10b5-1 trading plan. After this scheduled sale, she retains 24,353 shares (24.4K shares) in non-derivative holdings, with an additional 148,149 shares held through derivative securities (80,015 options and 68,134 options), meaning her overall position remains substantial. Her prior five trades at NAMS show a pattern of sales with 30-day returns ranging from +4.7% to +11.5% followed by 90-day declines ranging from -5.9% to -11.2%, suggesting post-sale price weakness has historically occurred within her trading window at this ticker. The company reports negative net income of $-48,441,000.00 ($-48.4M), annual revenue decline of -50.6%, and current revenue of only $3,040,000.00 ($3.0M), indicating material operational challenges that may inform the scheduled nature of this divestment.

NewAmsterdam CAO sold 72,428 shares for $2.3M in two sales (Jan 27–28) at $32.25 avg, reducing holdings by 74.8%

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., executed 2 separate sales totaling 72,428 shares for $2,335,859.52 at an average price of $32.25. This liquidation reduced her holdings from 96,781 shares to 24,353 shares, a 74.8% reduction. The sales occurred on 2026-01-27 and 2026-01-28 at transaction prices of $32.62 and $31.80, both above the current price of $31.44 but within the 52-week range of $14.90–$41.45. The company is unprofitable (net income of $-72,005,000.00 over its most recent full fiscal year) despite strong revenue growth of 223.4% year-over-year. At the same ticker, Kooij executed 4 prior sales in January 2026 (on 2026-01-23 and 2026-01-26, outcomes not yet measurable), and 1 sale on 2025-12-26 that showed a 30-day return of -5.6%, none measuring well-timed at the 90-day horizon. Her cross-ticker track record shows a 33.33% well-timed rate on 10 prior sells with an average 90-day return of 23.7% (indicating those prior sales were followed by stock gains, not losses)—a pattern inconsistent with successful sell-side timing.

NAMS Chief Accounting Officer sells 72,572 shares for $2.4M under scheduled 10b5-1 plan; holdings cut from 96.9K to 24.4K shares

Kooij Louise Frederika executed 4 separate sales totaling 72,572 shares for $2,415,843.11 on 2026-01-23 and 2026-01-26 at prices ranging from $32.77 to $34.37, reducing her holdings by 74.9% from 96,925 shares to 24,353 shares. The transaction is scheduled under a pre-arranged 10b5-1 trading plan, indicating this sale was not a discretionary decision but rather part of a predetermined portfolio management arrangement. The substantial reduction in her direct ownership stake—from approximately 96.9K to 24.4K shares—represents a material shift in her equity position at the company. This scale of liquidation, while executed through a scheduled mechanism, results in significantly diminished financial exposure to NewAmsterdam Pharma's future performance.

Chief Accounting Officer Kooij sells 145,000 shares ($5.2M) via scheduled 10b5-1 plan at NAMS

Kooij Louise Frederika, Chief Accounting Officer of NewAmsterdam Pharma, executed 3 separate sales totaling 145,000 shares for $5,196,740.65 across three trading days (2025-12-23 through 2025-12-26), with a blended average price of $35.84. The transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. Post-transaction holdings stand at 15,000 shares, down from 160,000 shares prior to these sales. As a C-suite executive in the company's financial reporting function, insider equity sales of this scale and concentration warrant investor attention, though the scheduled nature precludes timing-based inference.

CAO Kooij sells 150,000 shares (150.0K) in 2 transactions for $3,874,016.80, reducing stake by 90.9%; stock up 27.9% in 90 days

Chief Accounting Officer Louise Frederika Kooij sold 150,000 shares (150.0K shares) at blended average price $25.83 on 2025-09-09, reducing her holdings from 165,000 shares to 15,000 shares—a 90.9% reduction in stake. The sale occurred via 2 separate transactions (53,104 shares at $25.31 and 96,896 shares at $26.11), generating $3,874,016.80 in proceeds. NAMS shares traded at $26.90 on the filing date, within 0.4% of the 52-week high of $27.00, and have appreciated 27.9% over the trailing 90 days and 10.4% over 30 days, indicating strong recent momentum. The company posted revenue of $19,145,000.00 in its latest quarter but remains unprofitable with net income of $-17,364,000.00, despite annual revenue growth of 223.4%, marking a significant valuation disconnect during an expansion phase. Kooij's prior sell at this ticker on 2025-03-04 was well-timed at the 90-day horizon (stock fell after), and her cross-ticker track record shows 1 prior sell with a 100.00% well-timed rate, though the small sample size limits predictive inference.

CAO Kooij sells 150,000 shares (-90.9%) of NAMS at $20.37 on 3/4/25; company unprofitable

Chief Accounting Officer Louise Frederika Kooij sold 150,000 shares (150.0K shares) on 2025-03-04 at $20.37, reducing her holdings from 165,000 shares to 15,000 shares—a 90.9% reduction in position size. This is a substantial divestiture by the company's top accounting officer at a time when NewAmsterdam Pharma reported a negative net income of $-16,647,000.00 ($-16.6M) in its most recent full fiscal year, despite year-over-year revenue growth of 223.4%. The sale occurred $2.65 below the current price of $23.02, suggesting the transaction was not timed to recent strength; the stock has appreciated 27.4% over the 90 days following the transaction date. A near-complete exit by the Chief Accounting Officer at a cash-burn stage company merits investor scrutiny of the company's financial trajectory and liquidity runway.